Unnamed company reporting $20.18M revenue and $0.39M net income in 2025, total assets of ~$20.27M and an accumulated deficit of ~$897.4M, with material convertible-note and related-party financing activity.

# Unnamed Company

The excerpt appears to be the table of contents for Part I of a Form 10-K (or a similar filing). It lists the following items:

- Item 1. Business  
- Item 1A. Risk Factors  
- Item 1B. Unresolved Staff Comments  
- Item 1C. Cybersecurity  
- Item 1C or 1D. Properties (as shown)  
- Item 2. Legal Proceedings  
- Item 3. Mine Safety Disclosures  
- Item 4.

Next step:
- If you can share the actual text of Item 1 (Business) or the company’s financial statements (income statement, balance sheet, notes) from the filing, I can produce a precise markdown summary that includes counts and financial figures for customers, employees, revenue, and income.

Evofem Biosciences, Inc. is an innovative biopharmaceutical company focused on women's sexual and reproductive health through unique products like PHEXXI and SOLOSEC.

# Summary of Evofem Biosciences, Inc.

## Overview
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company based in San Diego, California, focusing on innovation in women's sexual and reproductive health. The company's mission is to develop and commercialize unique products that meet unmet needs in this sector. 

## Products
### 1. **PHEXXI**
- **Description**: PHEXXI is the first and only FDA-approved hormone-free prescription contraceptive vaginal gel. It is designed to be used by women to prevent pregnancy, applied within one hour prior to intercourse.
- **Launch Date**: Commercially launched in the U.S. in September 2020.
- **Unique Selling Proposition**: PHEXXI is applied on-demand, is hormone-free, and empowers women by giving them control over their contraception needs.
  
### 2. **SOLOSEC**
- **Description**: SOLOSEC is an FDA-approved oral antimicrobial agent used for the treatment of bacterial vaginosis (BV) and trichomoniasis (Trich).
- **Acquisition**: Evofem acquired global rights to SOLOSEC in July 2024, and it was relaunched in the U.S. in November 2024.
- **Usage**: SOLOSEC provides a complete course of therapy with a single dose.

## Financials
- **Employees**: 32 full-time employees as of March 14, 2025. The company employs consultants and contract workers as needed.
- **Revenue**: Approximately $11.2 million in accounts payable, but revenue details specifically tied to product sales are less defined in the provided context.
- **Net Income**: The company reported a non-cash gain of $53.0 million for the fiscal year ended December 31, 2023, primarily due to a gain on debt extinguishment, despite ongoing significant losses historically.

## Market Context
- **Target Customer Base**: The company primarily targets women of reproductive age. Specifically, there are 23.3 million women in the U.S. who are at risk of pregnancy and are not using hormone-based contraceptives, a significant potential market for PHEXXI. For SOLOSEC, the target audience consists of women suffering from BV and Trich, with BV affecting an estimated 21 million women in the U.S.
- **Market Competition**: The company competes with large pharmaceutical companies and generic products in the contraceptive market. It also relies on evolving market acceptance of its products for commercial success.

## Strategic Focus
The company’s primary focus includes:
- Successfully commercializing PHEXXI and SOLOSEC.
- Exploring partnerships and licensing agreements to expand product reach, particularly in international markets.
- Enhancing its sales force capabilities and leveraging telehealth platforms to reach more customers effectively.

## Challenges
Evofem faces several risks and challenges:
- It has incurred significant losses and anticipates continued negative cash flow.
- The company's financial health is under scrutiny, with doubts about its ability to continue as a going concern.
- Market competition is intense, with a high focus on regulatory compliance and intellectual property challenges.

In summary, Evofem Biosciences, Inc. is dedicated to providing innovative women's health solutions while navigating a complex landscape of financial and regulatory challenges.

Evofem Biosciences, Inc. is a San Diego-based biopharmaceutical company focused on women's sexual and reproductive health, known for its innovative product Phexxi, the first hormone-free prescription contraceptive vaginal gel.

## Company Overview: Evofem Biosciences, Inc.

### Business Focus
Evofem Biosciences is a San Diego-based commercial-stage biopharmaceutical company that specializes in women’s sexual and reproductive health. The company has a strong emphasis on innovation, highlighted by the development and commercialization of Phexxi, which is the first and only FDA-approved hormone-free prescription contraceptive vaginal gel.

### Product: Phexxi
- **Approval Date:** May 22, 2020
- **Launch Date:** September 2020 in the U.S.
- **Mechanism of Action:** Phexxi works by maintaining the vaginal pH at a level that is inhospitable to sperm, thereby preventing pregnancy. It is applied on-demand, allowing women to control their contraceptive needs discretely and flexibly.
- **Sales Performance:** Evofem has reported increased net product sales for each successive year since the launch of Phexxi.

### Market Opportunity
- **U.S. Contraceptive Market Value:** Valued at $8.7 billion in 2023 with an expected increase to approximately $12 billion by 2030, featuring a compound annual growth rate of 4.7%.
- **Target Population:** Approximately 23.3 million women in the U.S. who are currently at risk for pregnancy and are not using hormone-based contraceptives. This population includes 13 million women using no birth control method and 10.3 million relying on non-hormonal OTC options.

### Customers
Evofem’s primary customers include:
- Women of reproductive age, particularly those seeking non-hormonal contraceptive options.
- Healthcare professionals (HCPs) such as obstetricians and gynecologists who prescribe Phexxi.

### Company Size
- **Employees:** As of March 21, 2024, Evofem Biosciences has a total of 37 full-time employees and one part-time employee.
- **Sales Force:** The company has a dedicated sales team of 16 sales representatives, each with an average of 16 years of experience in the pharmaceutical industry, particularly in women’s health.

### Financial Overview
- **Revenue:** Evofem has generated revenue from sales of Phexxi, though specific revenue figures were not detailed in the provided text.
- **Profitability:** The company has been operating at a loss since its inception, reporting an accumulated deficit of approximately $888.7 million as of December 31, 2023.
- **Funding:** Evofem has primarily financed its operations through equity sales, debt arrangements, and product sales.

### Strategy and Future Growth
- **Commercialization Focus:** Evofem's immediate strategy is to successfully commercialize Phexxi in the U.S. and explore global opportunities through licensing agreements or partnerships.
- **Partnerships and Collaborations:** The company aims to leverage partnerships to expand its product offerings, enhance market presence, and enter territories outside the U.S. for Phexxi and future products.

### Challenges
Evofem Biosciences faces several challenges that could impact its operations and potential for growth, including:
- **Market Competition:** Competing against large pharmaceutical companies and a growing market for generic contraceptive products.
- **Financial Constraints:** The need for substantial capital to finance ongoing operations and marketing efforts, especially given its accumulated losses and reliance on external funding.
- **Regulatory Pressures:** Navigating complex FDA regulations and maintaining compliance with health care laws to avoid potential liabilities.

Overall, Evofem Biosciences is positioned uniquely within the women's health sector, focusing on innovative, non-hormonal contraceptive solutions. However, its financial health, operational challenges, and market dynamics pose significant hurdles to sustained growth and profitability.

Evofem Biosciences, Inc.

10-K / March 11, 2026

10-K / March 24, 2025

10-K / March 27, 2024

10-K / March 11, 2026

Unnamed Company